PBM Reform: Pharmacy Groups Call on Congress for Action

Pharmacy Groups ‍Urge Congressional Action on PBM Reform as Access ⁢Crisis Deepens

December 16, 2025 – A powerful coalition of pharmacy organizations has issued a stark warning to Congressional leaders:⁣ the time for Pharmacy Benefit Manager ⁣(PBM) reform is now. In a⁢ letter delivered friday,the groups detailed⁣ a rapidly escalating crisis in⁤ pharmacy access,fueled by unchecked PBM practices that⁢ inflate drug costs and⁣ force self-reliant pharmacies to close⁢ at an ‍alarming rate.

The letter, addressed to House Speaker Mike⁢ Johnson, House Minority Leader Hakeem Jeffries, Senate Majority Leader John Thune, and Senate Minority Leader Chuck Schumer, represents a unified front from key industry players including the National Association of Chain Drug Stores, the National Community Pharmacists Association, ‍the Food Industry Association, ⁣the⁤ National Grocers Association, the⁢ American Pharmacists Association, and‍ the National Association of Specialty Pharmacy. Their message is clear: continued inaction will have devastating consequences for patients and communities across the nation.

The PBM Problem: A Concentrated Market & Rising Costs

For years, PBMs ⁣have ‍operated with increasing scrutiny. These companies⁢ act as intermediaries between drug‍ manufacturers, insurance plans, ⁢and pharmacies, negotiating drug prices and managing prescription benefits. Though, their increasing vertical⁢ integration with insurance⁢ companies – the top three PBMs, CVS Caremark, Cigna’s Express Scripts, and unitedhealth Group’s Optum Rx, control roughly 80% of⁤ the market‍ – has led to concerns about ‍conflicts ⁢of interest and opaque pricing practices.

The core issue lies in how PBMs profit. Practices like “spread pricing,” where PBMs charge payers more for a drug than they reimburse the pharmacy, allowing them⁢ to pocket the ⁤difference, have come under fire.This lack of clarity directly contributes to higher drug costs for ‍patients and‍ squeezes the margins of pharmacies, particularly independent ones.

A Near Miss & A Worsening Situation

The urgency of the ⁢situation is underscored by a recent near-miss. A potential PBM crackdown was included in a federal spending bill in December 2024, only to be removed at the eleventh hour⁤ (as reported by MedCity News). Since ⁣then, ⁢the situation has demonstrably worsened.

“As‍ Congress’ near‑win on PBM reform in December 2024 – another missed opportunity that fell just short of enactment – the devastation ⁤of⁢ pharmacy⁤ access⁢ for patients⁢ and communities has only worsened,” the letter states. ⁢ The ⁢organizations report a‍ staggering⁤ net loss of over‍ six ⁣pharmacies per day – an ⁤acceleration of the nearly four-per-day closure rate seen in 2023 and 2024. Over 2,200 pharmacies ‍have closed in the last year alone, resulting in a net loss of over 13% of pharmacies since January 2018.

The ⁣Call for Concrete reforms

The coalition isn’t‍ simply highlighting the problem; they are advocating for specific, actionable reforms. Their key demands ⁤include:

*⁤ Medicaid Managed‍ Care Payment ‍Reform⁢ & Spread Pricing ban: Addressing unfair payment practices within Medicaid and eliminating the profit-driven practice of spread pricing.
* “Any ⁤Willing Pharmacy” Enforcement: ⁢ ⁤Requiring the Centers for Medicare &⁣ medicaid Services (CMS) ‍to clearly define and enforce fair contract terms ⁢in Medicare Part D, ensuring that all pharmacies willing‍ to meet legitimate requirements can participate in networks.
* decoupling PBM Compensation ⁢from List Prices: Prohibiting PBMs⁤ from basing their⁣ compensation on the list price of drugs ⁤in Medicare Part D, incentivizing them to negotiate lower net prices.
* Increased Transparency: ‍ Demanding‍ greater transparency in⁤ insurer claims and reimbursement practices, providing pharmacies with ⁣the data they⁣ need to understand and challenge unfair pricing.

“The ⁤failure to curb ⁣harmful PBM practices is no longer a crisis in the making – ⁢it now constitutes a crisis unaddressed,” the letter emphasizes. “Without⁣ PBM reform, patients are experiencing inflated drug costs, and many no longer have access to the pharmacy ⁤of their choice as pharmacies close and others are pushed out⁢ of network.”

Momentum ⁣Builds with New‍ Senate Bill

This call to action comes on the heels of a bipartisan effort in the Senate. Senators recently introduced the⁢ PBM Price transparency⁤ and Accountability ⁤act (as reported by MedCity‍ News),which aims to delink PBM compensation from rebates and ⁢increase reporting requirements to Medicare and the Department of‍ Health and Human Services (HHS).

the coalition urges Congress to include PBM reform in upcoming legislation, either as part of a larger package or as a⁢ standalone measure. ⁣”The consensus is broad,the policy ⁢is developed,and the

Leave a Comment